STUDY OF THE PARAMETERS OF TOLERABILITY AND ADHERENCE TO THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ARTERIAL HYPERTENSION ON THE BACKGROUND OF TREATMENT WITH FIXED COMBINATION OF RAMIPRIL AND AMLODIPINE (ACCORDING TO THE RESULTS OF OBSERVATIONAL STUDY "GRANAT-2")

Working group of the “GRANAT-2” study: Tula - Trubitsyn G.I., Ivanov Yu.V., Mirenkova O.K., Eskova R.A., Simonova R.P., Milon M.E., Telegina E.V., Kuznetsov A.M., Zhukova N.A., Zainullina I.K.; Rostov-on-Don - Budanov O.V., London E.M., Minosyan L.V., Nedashkovskaya N.G., Ter-Ananyants Ye.A.; Tomsk - Proskokova I.Yu., Permyakova O.V., Politova L.V., Maneeva I.D., Ivanova S.Yu.; Nizhny Novgorod - Larina O.V., Pokrovskaya I.N., Patselt E.A.; Moscow - Sladkova T.A., Zelenova Т.V. 

Aim. To study the tolerability and adherence to antihypertensive therapy in patients with hypertension and chronic obstructive pulmonary disease (COPD) using the fixed combination of ramipril and amlodipine in the observational program for patients with arterial hypertension and COPD (GRANAT-2). Material and methods. Patients with hypertension and COPD (n=52) with all inclusion criteria and without exclusion criteria who signed informed consent to participate in the GRANAT-2 program were included into the study. The use of a fixed combination of ramipril and amlodipine was recommended in all patients. The doses were determined by the treating physicians in accordance with the official drug instruction. The patients had 4 visits, and the duration of the study was 5 months. The Morisky-Green test was used to assess an adherence of patients to treatment. Assessments of blood pressure, adverse events were performed at all visits. Results. 50 of 52 patients completed the study: 45 patients used the studied fixed combination in the recommended doses, and 5 patients used other antihypertensive drugs, 2 patients withdrew from the study. Systolic blood pressure after 1 month of treatment decreased by an average of 20 mm Hg from the baseline, and diastolic blood pressure – by 10 mmHg. These rates after 5 months of therapy were 29 mm Hg and 15 mm Hg, respectively. Target blood pressure level was achieved in all patients. Increase in adherence of patients to treatment (according to the Morisky-Green test from 21.1% to 65.1%) was found. 2 cases of adverse events (dry cough) were registered. The discrepancy in adherence assessment was revealed between the results from the Morisky-Green test and the data from program case report forms. Conclusion. Regular patient visits to the doctor and the rapid achievement of an antihypertensive effect with good tolerability of a fixed combination of ramipril and amlodipine contributed to the increase in adherence of patients to treatment. Undesirable effects of the drug therapy are significant, but not leading factors that have a negative impact on the patient adherence to treatment.

1. Chronic obstructive pulmonary disease (COPD). Information Bulletin of the WHO, N315, January 2015. Available at: http://www.who.int/mediacentre/factsheets/fs315/en/. Checked by March 15, 2017

2. Karoli N.A., Rebrov A.P. Сomorbidity in patients with chronic obstructive pulmonary disease: a role of cardiovascular disorders. Rational Pharmacotherapy in Cardiology. 2009;5(4):9-16. (In Russ.) [Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная Фармакотерапия в Кардиологии. 2009;5(4): 9-16].

3. Yakhontov D.A., Balabanova N.F. Effects of calcium antagonists of the third generation in patients with arterial hypertension and concomitant chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2010;6(3):339-44. (In Russ.) [Яхонтов Д.А., Балабанова Н.Ф. Возможности антагонистов кальция третьего поколения в лечении больных артериальной гипертензией в сочетании с хронической обструктивной болезнью легких. Рациональная Фармакотерапия в Кардиологии. 2010; 6(3):339-44].

4. Kaplon N.M. The CARE study: a postmarketing evalution of ramipril in 11.100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther. 1996;18(4):658-70.

5. Lukina Yu.V., Ginzburg, M. L., Smirnov V. P., et al. Adherence to treatment preceding hospitalization in patients with acute coronary syndrome. Klinitsist. 2012;6(2):41-9. (In Russ.) [Лукина Ю.В., Гинзбург М.Л., Смирнов В.П., Кутишенко Н.П., Марцевич С.Ю. Приверженность лечению, предшествующему госпитализации, у пациентов с острым коронарным синдромом. Клиницист. 2012;6(2):41-9]

6. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2014;23(1):3-16.

7. Yusuf S, Sleight P, Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.

8. Svensson P., Faire U., Sleight P. et al. Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures. A HOPE Substudy. Hypertension. 2001;38:28-32

9. Lukina Y.V., Martsevich S.Y. Combination therapy of hypertension — a reliable way to target achieve. Rational Pharmacotherapy in Cardiology. 2010; 6(6):859-64. (In Russ.) [Лукина Ю.В., Марцевич С.Ю. Комбинированная терапия артериальной гипертонии — надежный путь достижения цели. Рациональная Фармакотерапия в Кардиологии. 2010;6(6):859-64].

10. Martsevich S.Y., Gaysenok O.V., Tripkosh S.G. et al. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFIL registry). Rational Pharmacotherapy in Cardiology. 2013; 9(2):133-7. (In Russ.) [Марцевич С.Ю., Гайсенок О.В., Трипкош С.Г. и соавт. Наблюдение в специализированном медицинском центре и качество гиполипидемической терапии у пациентов с сердечно-сосудистыми заболеваниями (по данным регистра ПРОФИЛЬ). Рациональная Фармакотерапия в Кардиологии. 2013;9(2):133-7]

11. Chapman R.H., Petrilla A.A., Benner J.S., et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008; 25(10):885-92.

12. Semenova Y.V., Kutishenko N.P., Zagebelnyy A.V. et al. Adherence to attendance at outpatient clinic, quality of prehospital therapy, and direct outcome of acute coronary syndrome: analysis within LIS3 registry. Rational Pharmacotherapy in Cardiology. 2016;12(4):430-4. (In Russ.) [Семенова Ю.В., Кутишенко Н.П., Загребельный А.В. и соавт. Приверженность к посещению лечебно- профилактических учреждений, качество терапии и ближайшие исходы острого коронарного синдрома: исследование в рамках регистра ЛИС-3. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):430-4]

13. Pineiro F., Gil V., Donis M., Orozco D. et al. The validity of 6 indirect methods for assessing drug treatment compliance in arterial hypertension. Aten Primaria. 1997;19(7):372-4.

14. Lukina Y.V., Martsevich S.Y., Kutishenko N.P. The Moriscos-Green scale: the pros and cons of universal test, correction of mistakes. Rational Pharmacotherapy in Cardiology. 2016; 12(1):63-5. (In Russ.) [Лукина Ю.В., Марцевич С.Ю., Кутишенко Н.П. Шкала Мориски-Грина: плюсы и минусы универсального теста, работа над ошибками. Рациональная Фармакотерапия в Кардиологии. 2016;12(1):63-5].

15. Morisky D.E., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5): 348-54